Beximco Pharma receives second product approval from the US FDA

25 October 2016

Beximco Pharmaceuticals (AIM: BXP) has received US Food and Drug Administration approval for sotalol hydrochloride, a generic version of the cardiovascular drug Betapace, originally developed by Bayer legacy company Schering AG and first approved in 1992, following submission of an Abbreviated New Drug Application (ANDA) in June 2014.

This is the second product from Beximco Pharma, largest manufacturer and exporter of generic and active pharmaceuticals ingredients in Bangladesh, to be approved by the US FDA after carvedilol, a prescription drug for treating hypertension, which was approved in July 2015.

This approval will allow Beximco Pharma to produce sotalol tablets in different strengths, ie, 80mg, 120mg and 160mg. The company expects to launch this product during the first quarter of 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK